Denileukin Diftitox Articles
Expanded US indication for Eisai's Ontakr
20 October 2008
Japan stock market week to Oct 30, 2006
6 November 2006
Ligand finalizes sale of oncology line to Eisai
6 November 2006
Japan stock market week to Sept 11, 2006
18 September 2006
Ligand sells oncology line to Eisai and Avinza to King for total $518M
18 September 2006
Ligand's 1st-qtr 2006 revenues up 38%
29 May 2006
Ligand buys down Ontak royalties
18 April 2005
Ligand to buy down Lilly Ontak royalties
17 January 2005
Ligand sets up pain and oncology units
15 November 2004
Ligand raises $47M in private placing
22 September 2003
R&D costs offset 140% sales rise at Ligand
18 August 2003
Ligand's 2nd-qtr revenues up 10%, despite 15% loss growth
19 August 2002
Ligand launches Avinza in USA
15 July 2002
New data on Ligand's Targretin, Ontak
27 May 2002
Stock Commentary - New York
27 May 2002
Ligand revenues leap 59%, as product sales double
18 March 2002
Ligand submits European MAA for Onzar
7 January 2002
Ligand submits European MAA for Onzar
20 December 2001
Amevive out in front amongst new biologicals for psoriasis
16 October 2001
Ligand's Targretin capsules cleared in EU
5 April 2001
Ligand's Targretin gel nears full US approval
14 June 2000
Ligand sells Marathon assets for $10 million
11 January 2000
Ligand completes marketing deal in Italy
7 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Ontak tested in NHL
20 May 1999
FDA approves Ligand's Ontak for cutaneous T cell lymphoma
11 February 1999
Ligand Takes $30 Mill 3rd-Qtr Charge
20 November 1998
ALRT Buyback Affects Revenues At Ligand
24 August 1998
Cancer News In Brief
18 June 1998
FDA C'tee Gives OK To Seragen's Ontak
4 June 1998
Ligand Announces Lilly, Seragen & Marathon Deals
12 May 1998
Seragen Files BLA For T-Cell Lymphoma Drug
18 December 1997
Showing 1-36 of 36 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
